@kervio, thanks for your comments on this. I am also really shocked at the primary endpoint being set at a 43% improvement in mortality. I can't see how they would ever realistically have got overwhelming efficacy (e.g. using a sceptical prior) at any interim analysis if this was the goal.
I'm no expert at Bayesian analysis but I had a go at estimating some probability distributions for achieving various levels of mortality reduction for various observed deaths in the treatment arm at the 45% analysis stage (which obviously passed futility). I inferred some mean and standard deviations for both sceptical and enthusiastic priors under various scenarios. I have plotted these below for a particular scenario where 17 deaths were observed in the treatment arm and where there were theoretical deaths of 40.5 (i.e. mortality at 60%) in the control arm. This, I think, would be the 'worst case scenario' / maximum no of deaths that could have been observed at that the 45% stage for continuation of the trial. This also assumes NIH/MSB based futility analysis on an enthusiastic prior and selected 5% as the minimum required probability of achieving the endpoint.
If 17 deaths vs. 40.5 is in fact the worst case, that's still quite a treatment benefit!
- Forums
- ASX - By Stock
- Overwhelming efficacy - the stats required
@kervio, thanks for your comments on this. I am also really...
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B |
Open | High | Low | Value | Volume |
$1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 61090 | $1.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 239558 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 61090 | 1.015 |
1 | 700 | 1.010 |
9 | 123952 | 1.005 |
34 | 516697 | 1.000 |
1 | 25000 | 0.995 |
Price($) | Vol. | No. |
---|---|---|
1.030 | 17500 | 1 |
1.035 | 54000 | 2 |
1.040 | 41250 | 2 |
1.045 | 68050 | 4 |
1.050 | 45395 | 3 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online